The observed curative effect seen in animal models of leukemia growth following administration of anti-NG2/CSPG4 antibodies has been attributed to a putative role of proteoglycan in agonizing with bone-marrow resident cells in creating a chemoprotective microenvironment. Here, CSPG4 is linked to leukemia.